Given the efficacy of anti‐VEGF in suppressing CNV, future clinical strategies might explore the potential synergistic effects of combining PD‐L1 and anti‐VEGF therapies, potentially mirroring dual‐specificity antibody treatments used in cancer therapy.[86] Additionally, the cellular distribution of VEGF signaling warrants further exploration to fully understand its role in the CNV. The gene discussed is CD274; the disease is cancer.